Bessemer Group
NKTR icon

Bessemer Group’s Nektar Therapeutics NKTR Stock Holding History

Bessemer Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Sell
1,565
-15
-0.9% -$854 ﹤0.01% 1495
2025
Q4 		$66K Buy
1,580
+15
+1% +$839 ﹤0.01% 1569
2025
Q3 		$90K Buy
1,565
+1,480
+1,741% +$49K ﹤0.01% 1304
2025
Q2 		$2K Buy
+85
New +$954 ﹤0.01% 2228
2019
Q4 		– Sell
-11
Closed -$3K – 1727
2019
Q3 		$3K Sell
11
-11
-50% -$4.03K ﹤0.01% 1574
2019
Q2 		$12K Sell
22
-23
-51% -$11.5K ﹤0.01% 1469
2019
Q1 		$23K Buy
45
+4
+10% +$2.37K ﹤0.01% 1402
2018
Q4 		$20K Buy
41
+40
+4,000% +$24.1K ﹤0.01% 1513
2018
Q3 		$1K Hold
1
– – ﹤0.01% 1787
2018
Q2 		$1K Buy
+1
New +$1.15K ﹤0.01% 1646
2017
Q1 		– Sell
-5
Closed -$1K – 1860
2016
Q4 		$1K Buy
5
+1
+25% +$203 ﹤0.01% 1900
2016
Q3 		$1K Hold
4
– – ﹤0.01% 1768
2016
Q2 		$1K Sell
4
-368
-99% -$82.3K ﹤0.01% 1271
2016
Q1 		$77K Buy
372
+368
+9,200% +$70.7K ﹤0.01% 826
2015
Q4 		$1K Sell
4
-185
-98% -$38K ﹤0.01% 1537
2015
Q3 		$31K Hold
189
– – ﹤0.01% 1040
2015
Q2 		$36K Hold
189
– – ﹤0.01% 1034
2015
Q1 		$32K Hold
189
– – ﹤0.01% 1052
2014
Q4 		$44K Buy
+189
New +$40.4K ﹤0.01% 962

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bessemer Group's NKTR Position: Q1 2026 in Review

Bessemer Group reduced its Nektar Therapeutics (NKTR) stake by 0.95% in Q1 2026, selling an estimated $854 and leaving 1,565 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1495.

Bessemer Group first reported a position in NKTR in Q4 2014 and has held it in 19 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Bessemer Group held 1,565 shares of Nektar Therapeutics worth $112K as of Q1 2026.
  • Bessemer Group sold 15 Nektar Therapeutics shares in Q1 2026, an estimated $854.
  • Nektar Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #1495 holding.
  • Bessemer Group first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 19 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.